Heart failure hospitalization with SGLT-2 inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled and Observational Studies.

Heart failure hospitalization with SGLT-2 inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled and Observational Studies. Expert Rev Clin Pharmacol. 2019 Feb 28;: Authors: Singh AK, Singh R Abstract INTRODUCTION: Heart failure (HF) in type 2 diabetes mellitus (T2DM) poses a significant increase in mortality. Until recently, anti-diabetic drugs have not been shown to reduce hospitalization due to heart failure (hHF). While thiazolidinedione class and saxagliptin has shown a significantly increased risk, sodium-glucose linked co-transporter 2 inhibitors (SGLT-2Is) have demonstrated a significant reduction in the risk of hHF. Areas covered: We systematically searched the database of PubMed, Embase, ClinicalTrials.gov and International conference presentation up to December 25, 2018 and retrieved all the studies that were conducted for ≥24 weeks and explicitly reported hHF outcome. Subsequently, we conducted the meta-analysis to study the effect of SGLT-2Is on hHF outcome in randomized controlled trials (RCTs), observational studies and both. Expert opinion: The meta-analysis of RCTs (N=34,322), observational studies (N=15,36,339) and both (N=15,70,661), demonstrated a significant decrease in hHF (OR 0.70, 0.64, 0.66 respectively, all p=0.000) with SGLT-2Is compared to placebo or other anti-diabetes drugs in T2DM. Significant benefit in hHF (OR 0.68, p=0.000) is also observed in patients with established HF (N=389...
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research